Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nivoxia-MR
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Nivoxia-MR** is an oral fixed-dose analgesic and muscle-relaxant tablet marketed by Vin Medicament for pain associated with acute muscle spasm. Each tablet contains etoricoxib 60 mg, a selective cyclooxygenase-2 inhibitor that reduces prostaglandin-mediated pain and inflammation, and thiocolchicoside 4 mg, a centrally acting muscle relaxant. ([1mg.com](https://www.1mg.com/drugs/nivoxia-mr-tablet-1038220))
- Brand names
- Nivoxia-MR
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Nivoxia-MR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nivoxia-MR.